Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 15, 2006, reporting the entry into a material definitive agreement. Specifically, the company entered into an Underwriting Agreement with Morgan Stanley & Co. Incorporated on November 13, 2006. This agreement outlines the issuance and sale of 7,600,000 shares of the company's common stock. The offering was registered under an effective Form S-3 registration statement with the SEC, indicating that the shares being sold are subject to regulatory approval for public offering. Investors should note that this filing primarily concerns the procedural aspect of a stock offering, not the underlying business performance or new drug development, which would typically be detailed in other filings or press releases.
Key Highlights
- 1Regeneron Pharmaceuticals entered into an Underwriting Agreement with Morgan Stanley & Co. Incorporated on November 13, 2006.
- 2The agreement pertains to the issuance and sale of 7,600,000 shares of Regeneron's common stock.
- 3The sale of these shares is registered under an effective Form S-3 registration statement.
- 4This filing constitutes reporting the entry into a material definitive agreement (Item 1.01).
- 5The primary purpose of the 8-K is to disclose the details of this stock offering agreement.
- 6No financial statements or other exhibits beyond the Underwriting Agreement are listed in this filing.
- 7Stuart Kolinski, Vice President and General Counsel, signed the filing on behalf of the company.